Actively Recruiting
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
Led by Concord Repatriation General Hospital · Updated on 2021-09-08
476
Participants Needed
10
Research Sites
269 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected at the early stage. Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors such as operator experience, patient body habitus and liver parenchymal heterogeneity due to chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound can be suboptimal or near non-diagnostic. Currently no guideline offers an alternative surveillance tool for patients who have suboptimal surveillance ultrasounds.
CONDITIONS
Official Title
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with cirrhosis from any cause except rare causes like vascular or congenital fibrosis and with reduced liver visualization on ultrasound
- Cirrhosis diagnosed by liver biopsy, signs of past liver decompensation, or clinical suspicion plus imaging or Fibroscan results
- No previous history or current suspicion of hepatocellular carcinoma confirmed by imaging within 6 months
- Ability to comply with study visits and procedures as judged by the investigator
- Willingness to provide written informed consent
You will not qualify if you...
- Contraindications to MRI such as defibrillator, pacemaker, metallic foreign bodies, or severe claustrophobia
- Contraindications to gadolinium contrast
- Age under 20 years or over 85 years
- Pregnancy or breastfeeding
- Any condition that the investigator believes makes the patient unsuitable for the study or may interfere with study completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Not Yet Recruiting
2
Concord Repatriation General Hospital
Concord, New South Wales, Australia, 2139
Actively Recruiting
3
Gosford Hospital
Gosford, New South Wales, Australia
Not Yet Recruiting
4
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Not Yet Recruiting
5
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Not Yet Recruiting
6
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Not Yet Recruiting
7
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia, 3065
Not Yet Recruiting
8
Austin Hospital
Heidelberg, Victoria, Australia, 3084
Not Yet Recruiting
9
Royal Perth Hospital
Perth, Western Australia, Australia
Not Yet Recruiting
10
North Shore Hospital
Takapuna, Auckland, New Zealand, 0620
Not Yet Recruiting
Research Team
J
Jessica Yang, MBBS
CONTACT
I
Isaac Lui, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here